# ALung Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alung-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Pittsburgh, US
- Website: www.alung.com
- Total disclosed funding: $82M
- Latest round: Series C (Apr 11, 2017)
- Investors on record: 14

## About

ALung Technologies, Inc. is a medical device company focused on developing innovative respiratory support solutions to improve patient outcomes during critical care. Their technologies target advanced lung therapies using extracorporeal carbon dioxide removal.Founded in 1997, ALung Technologies, Inc. is headquartered in Pittsburgh, US, specializing in respiratory technology. The company raised USD 3.25 mn in VENTURE DEBT on January 15, 2020, contributing to a total of USD 36.00 mn raised across 12 deals. CEO Pete Decomo leads the organization, which has not publicly indicated any significant shifts in business strategy or operations.ALung Technologies develops advanced medical devices aimed at providing vital respiratory support. Their key product is the Hemolung RAS, which is designed for patients with acute respiratory failure, offering extracorporeal carbon dioxide removal to enhance their respiratory efficiency. This technology is intended to support healthcare providers in delivering optimal care in critical situations.ALung Technologies generates revenue primarily through the sale of its Hemolung RAS systems and associated services, targeting hospitals and healthcare providers. The company's business model revolves around direct sales to medical institutions, supplemented by ongoing service agreements and partnerships that ensure consistent supply and operational support for their technologies.In the coming years, ALung Technologies plans to introduce new iterations of the Hemolung RAS, with product launches expected to enhance performance and usability. The company is targeting expansion into European and Asian markets by 2023 to broaden its geographical reach. Recent funding raised in January 2020 will be utilized to support product development and market entry initiatives, further solidifying their presence in the global respiratory care market.

## Funding rounds

- Series C, Apr 11, 2017, $36M — Allos Ventures, The Accelerator Group, Riverfront Ventures, Birchmere, UPMC Enterprises, BlueTree Venture Fund, Philips Electronics North America Corporation, Abiomed, Inc.
- Series B, Sep 11, 2013, $16M — Allos Ventures, Smithfield Trust, Pittsburgh Life Sciences Greenhouse, BlueTree Allied Angels, West Capital Advisors, Birchmere
- Series B, Feb 6, 2012, $10M — Eagle Ventures, Birchmere
- Series B, Nov 11, 2011, $6.6M — Birchmere, Rosetta Capital Corporation
- Series A, Oct 11, 2010, $14M — Eagle Ventures, Birchmere

## Investors

- Eagle Ventures (https://capitalatlas.ai/funds/eagle-ventures) — Series A, Series B
- Birchmere (https://capitalatlas.ai/funds/birchmere) — Series A, Series B, Series C
- Rosetta Capital Corporation (https://capitalatlas.ai/funds/rosetta-capital-corporation) — Series B
- Allos Ventures (https://capitalatlas.ai/funds/allos-ventures) — Series B, Series C
- Smithfield Trust — Series B
- Pittsburgh Life Sciences Greenhouse (https://capitalatlas.ai/funds/pittsburgh-life-sciences-greenhouse) — Series B
- BlueTree Allied Angels — Series B
- West Capital Advisors (https://capitalatlas.ai/funds/west-capital-advisors) — Series B
- The Accelerator Group — Series C
- Riverfront Ventures (https://capitalatlas.ai/funds/riverfront-ventures) — Series C
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series C
- BlueTree Venture Fund (https://capitalatlas.ai/funds/bluetree-venture-fund) — Series C
- Philips Electronics North America Corporation — Series C
- Abiomed, Inc. — Series C